Loading
companiesCompany
CytoReason
CytoReason builds computer models of human diseases from molecular and clinical data so drug companies can predict which targets and drugs are most likely to work, including in cancer immunotherapy.
Overview
CytoReason, founded in 2016 and headquartered in Tel Aviv with a US hub in Cambridge, Massachusetts, advances computational disease biology: it integrates human molecular and clinical data into computational disease models that give pharmaceutical and biotechnology companies predictive insights on assets, targets and indications. The platform spans immunology, inflammation, immuno-oncology and metabolism, and the company states that six of the world's top ten pharmaceutical companies use it, with Sanofi and Pfizer among disclosed partners. In July 2024 CytoReason announced an USD 80 million financing with investors including OurCrowd, NVIDIA, Pfizer and Thermo Fisher Scientific; the release does not name the round, so it is not recorded as a structured funding entry.
Headquarters
Tel Aviv, IL
Funding
All startupsGrowth stage
Investors
Type
Stage
Growth stage
Website
Founded
2016
Notes
top- USD 80 million financing (July 2024) is sourced but the release gives no round label, so it is described in the summary rather than in funding. Website is a JavaScript application; content was read from static .dc.html pages found in the sitemap.